06.04.2021 • News

Sinovac Aims for 2 Billion Covid Vaccines Annually

Chinese vaccine manufacturer Sinovac has doubled projected annual output of its Covid-19 shot to 2 billion doses per year, up from the 1 billion estimated in February this year when it received Chinese government approval. The company said last week it had started up a new commercial plant.

Already, Sinovac said it has delivered some 200 million doses of its vaccine to more than 20 countries, with more than 100 million doses already administered around the world. Its product has received emergency authorization or conditional marketing approval in more than 30 countries, including Turkey, Mexico and Indonesia.

Like the AstraZeneca shot, efficacy figures for Sinovac have bounced around. After reports from Brazil said it was 78% effective, the figure was later downgraded to 50.4%. Adding to the confusion, interim data from a Phase 3 trial in Turkey put the figure at 91.25%.

Author: Dede Williams, Freelance Journalist

Chinese vaccine manufacturer Sinovac has doubled projected annual output of its...
Chinese vaccine manufacturer Sinovac has doubled projected annual output of its Covid-19 shot to 2 billion doses per year, up from the 1 billion estimated in February this year when it received Chinese government approval. (c) Hakan Nural

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

most read